WAYLIVRA

This brand name is authorized in Austria, Estonia, France, Ireland, Lithuania, Poland, Romania, United Kingdom

Active ingredients

The drug WAYLIVRA contains one active pharmaceutical ingredient (API):

1 Volanesorsen UNII 6JON30SLDT - VOLANESORSEN SODIUM

Volanesorsen is an antisense oligonucleotide designed to inhibit the formation of apoC-III, a protein that is recognised to regulate both triglyceride metabolism and hepatic clearance of chylomicrons and other triglyceride-rich lipoproteins. Read about Volanesorsen

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
WAYLIVRA Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AX	Other lipid modifying agents	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain
Discover more medicines within C10AX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1795956, 1795967
Country: FR	Base de données publique des médicaments	Identifier(s): 65766872
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 376465
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087707, 1087708
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100421193
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W67657001, W67657002